Filtered By:
Management: Funding
Therapy: Cancer Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 49 results found since Jan 2013.
A National Cancer Grid pooled procurement initiative, India
This study reveals the advantages of group negotiation in pooled procurement for high-value medicines, an approach that can be applied to other health systems.PMID:37638358 | PMC:PMC10452934 | DOI:10.2471/BLT.23.289714
Source: Bulletin of the World Health Organization - August 28, 2023 Category: International Medicine & Public Health Authors: C S Pramesh Manju Sengar Sumedha Patankar Girish Chinnaswamy Sudeep Gupta M Vijayakumar Sanjeev Sood Anil N Sathe Venkatraman Radhakrishnan Prasanth Ganesan Krishna Mohan Mallavarapu Rajendra A Badwe Source Type: research
Health-related quality of life and pain outcomes with < sup > 177 < /sup > LuLu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4.ABSTRACTBACKGROUND: In VISION, the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) improved radiographic progression-free survival and overall survival when added to protocol-permitted standard of care in patients with metastatic castration-resistant prostate cancer. Here, we report additional health-related quality of life (HRQOL), pain, and symptomatic skeletal event results.METHODS: This multicentre, open-label, randomised, phase 3 trial was conducted at 84 cancer centre...
Source: Cancer Control - June 3, 2023 Category: Cancer & Oncology Authors: Karim Fizazi Ken Herrmann Bernd J Krause Kambiz Rahbar Kim N Chi Michael J Morris Oliver Sartor Scott T Tagawa Ayse T Kendi Nicholas Vogelzang Jeremie Calais James Nagarajah Xiao X Wei Vadim S Koshkin Jean-Mathieu Beauregard Brian Chang Ray Ghouse Michell Source Type: research
Patient-centred, self-funding dose optimisation trials as a route to reduce toxicity, lower cost and improve access to cancer therapy
Ann Oncol. 2023 May 23:S0923-7534(23)00687-7. doi: 10.1016/j.annonc.2023.05.006. Online ahead of print.NO ABSTRACTPMID:37230253 | DOI:10.1016/j.annonc.2023.05.006
Source: Ann Oncol - May 25, 2023 Category: Cancer & Oncology Authors: Ian F Tannock Gauthier Bouche Daniel A Goldstein Yasushi Goto Allen S Lichter Kumar Prabhash Priya Ranganathan Leonard B Saltz Gabe S Sonke Garth W Strohbehn Roger von Moos Mark J Ratain Source Type: research
Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort
Lancet. 2023 Apr 5:S0140-6736(22)02471-0. doi: 10.1016/S0140-6736(22)02471-0. Online ahead of print.ABSTRACTBACKGROUND: 5-year survival after childhood cancer does not fully describe life-years lost due to childhood cancer because there are a large number of deaths occurring beyond 5-years (late mortality) related to cancer and cancer treatment. Specific causes of health-related (non-recurrence, non-external) late mortality and risk reduction through modifiable lifestyle and cardiovascular risk factors are not well described. Through using a well-characterised cohort of 5-year survivors of the most common childhood cancers...
Source: Cancer Control - April 8, 2023 Category: Cancer & Oncology Authors: Stephanie B Dixon Qi Liu Eric J Chow Kevin C Oeffinger Paul C Nathan Rebecca M Howell Wendy M Leisenring Matthew J Ehrhardt Kirsten K Ness Kevin R Krull Ann C Mertens Melissa M Hudson Leslie L Robison Yutaka Yasui Gregory T Armstrong Source Type: research
Current Scenario of Clinical Cancer Research in Latin America and the Caribbean
Curr Oncol. 2023 Jan 4;30(1):653-662. doi: 10.3390/curroncol30010050.ABSTRACTIn Latin America and the Caribbean (LAC), progress has been made in some national and regional cancer control initiatives, which have proved useful in reducing diagnostic and treatment initiation delays. However, there are still significant gaps, including a lack of oncology clinical trials. In this article, we will introduce the current status of the region's clinical research in cancer, with a special focus on academic cancer research groups and investigator-initiated research (IIR) initiatives. Investigators in LAC have strived to improve cance...
Source: Cancer Control - January 20, 2023 Category: Cancer & Oncology Authors: Gustavo G össling Taiane F Rebelatto Cynthia Villarreal-Garza Ana S Ferrigno Denisse Bretel Raul Sala Juliana Giacomazzi William N William Gustavo Werutsky Source Type: research
Fight Aging! Newsletter, July 11th 2022
In this study we employ a transcriptome-wide and multi-tissue approach to analyze the influence of both LTDR and short-term DR (STDR) at old age on the aging phenotype. We were able to characterize a common transcriptional gene network driving inflammaging in most of the analyzed tissues. This network is characterized by chromatin opening and upregulation in the transcription of innate immune system receptors and by activation of interferon signaling through interferon regulatory factors, inflammatory cytokines, and Stat1-mediated transcription. We also found that both DR interventions ameliorate this inflammaging phenotyp...
Source: Fight Aging! - July 10, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, May 2nd 2022
In this study, we tested the therapeutic potential of VHHASC and a newly generated VHH against murine ASC (VHHmASC) to target ASC specks in vitro and in vivo. We show that pre-incubation of extracellular ASC specks with VHHASC abrogated their inflammatory functions in vitro. Recombinant VHHASC rapidly disassembled pre-formed ASC specks and thus inhibited their ability to seed the nucleation of soluble ASC. Notably, VHHASC required prior cytosolic access to prevent inflammasome activation within cells, but it was effective against extracellular ASC specks released following caspase-1-dependent loss of membrane integrity, an...
Source: Fight Aging! - May 1, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
Lancet Oncol. 2022 Feb 11:S1470-2045(22)00017-1. doi: 10.1016/S1470-2045(22)00017-1. Online ahead of print.ABSTRACTBACKGROUND: The PROfound study showed significantly improved radiographical progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer with alterations in homologous recombination repair genes and disease progression on a previous next-generation hormonal drug who received olaparib then those who received control. We aimed to assess pain and patient-centric health-related quality of life (HRQOL) measures in patients in the trial.METHODS: In this open-label, rando...
Source: Pain Physician - February 14, 2022 Category: Anesthesiology Authors: Antoine Thiery-Vuillemin Johann de Bono Maha Hussain Guilhem Roubaud Giuseppe Procopio Neal Shore Karim Fizazi Gabriel Dos Anjos Gwenaelle Gravis Jae Young Joung Nobuaki Matsubara Daniel Castellano Arnold Degboe Chris Gresty Jinyu Kang Allison Allen Chris Source Type: research
Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association
Circulation. 2021 Nov 10:CIR0000000000001032. doi: 10.1161/CIR.0000000000001032. Online ahead of print.ABSTRACTImproving cancer survival represents the most significant effect of precision medicine and personalized molecular and immunologic therapeutics. Cardiovascular health becomes henceforth a key determinant for the direction of overall outcomes after cancer. Comprehensive tissue diagnostic studies undoubtedly have been and continue to be at the core of the fight against cancer. Will a systemic approach integrating circulating blood-derived biomarkers, multimodality imaging technologies, strategic panomics, and real-ti...
Source: Circulation - November 10, 2021 Category: Cardiology Authors: Vlad G Zaha Salim S Hayek Kevin M Alexander Theresa M Beckie W Gregory Hundley Lavanya Kondapalli Bonnie Ky Kasey J Leger Wouter C Meijers Javid J Moslehi Svati H Shah American Heart Association Cardio-Oncology Subcommittee of the Council on Clinical Card Source Type: research
